Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Breast Cancer Female × darolutamide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 24 Salivary Gland Neoplasms 3 Metastatic Castration-resistant Prostate Cancer 2 Triple Negative Breast Neoplasms 1 Prostatic Neoplasms, Castration-Resistant 1 Neoplasms 1 Neoplasm Metastasis 1 High-Risk Localized Prostate Cancer 1 Granulosa cell tumor of the ovary 1 Carcinoma, Intraductal, Noninfiltrating 1 Bulbo-Spinal Atrophy, X-Linked 1 Breast Cancer Female 1 Biochemically Recurrent Prostate Cancer 1

Interventions

Tamoxifen 2 Paclitaxel 2 pyrotinib 1 pembrolizumab 1 palbociclib 1 iniparib 1 darolutamide 1 Thioctic Acid 1 Pentoxifylline 1 Metformin 1 Doxorubicin 1 Cyclophosphamide 1 Capecitabine 1 Aromatase Inhibitors 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03383679 2022-11-21

START

UNICANCER

Phase 2 Completed

Breast Cancer Female

Data powered by HemOnc (CC BY 4.0) Colophon ⚡